REPL Replimune Group Inc

Price (delayed)

$9.7

Market cap

$814.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.38

Enterprise value

$715.13M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary ...

Highlights
The company's equity has shrunk by 60% YoY and by 21% QoQ
Replimune Group's debt has increased by 47% YoY and by 46% from the previous quarter

Key stats

What are the main financial stats of REPL

REPL stock price

How has the Replimune Group stock price performed over time
Intraday
-7.27%
1 week
-5.18%
1 month
-13.93%
1 year
212.9%
YTD
-0.21%
QTD
-12.38%

Financial performance

How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$319.92M
Net income
-$313.94M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 27% YoY
The operating income has declined by 22% year-on-year

Price vs fundamentals

How does REPL's price correlate with its fundamentals

Growth

What is Replimune Group's growth rate over time

Valuation

What is Replimune Group stock price valuation
P/E
N/A
P/B
4.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 10% YoY
REPL's price to book (P/B) is 119% higher than its 5-year quarterly average of 2.2 and 79% higher than its last 4 quarters average of 2.7
The company's equity has shrunk by 60% YoY and by 21% QoQ

Efficiency

How efficient is Replimune Group business performance
REPL's ROE has shrunk by 122% YoY and by 25% QoQ
Replimune Group's return on invested capital has shrunk by 102% YoY and by 24% QoQ
Replimune Group's return on assets has shrunk by 82% YoY and by 14% QoQ

Dividends

What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REPL.

Financial health

How did Replimune Group financials performed over time
The total assets is 100% more than the total liabilities
Replimune Group's quick ratio has decreased by 41% YoY and by 15% from the previous quarter
The total assets is down by 40% YoY
Replimune Group's debt is 33% less than its equity
The debt to equity has surged by 86% since the previous quarter
The company's equity has shrunk by 60% YoY and by 21% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.